Pre-EclampsiaNCT03630276
Evaluation of Neutrophil/Lymphocyte Ratio ,Platelet/Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia
A study testing Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP in people with Pre-Eclampsia, run by Ain Shams University at 1 site in Egypt.
Trial summary
Evaluation of neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP as markers of severity of Pre-eclampsia Read more about this study
- Who is it for?
- Ages 25 to 45 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Pre-Eclampsia
- What is being tested?
- Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 111 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Aug 2018to 10 Aug 2018
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 25 to 45 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- PREECLAMPSIA from 25_45years
Who cannot join
- chronic diseases Primary hypertension
Trial locations and contacts
1 site in 1 country.
Egypt1 site, 1 recruiting
- Recruiting
Shaza
Alexandria, Alex, 12345
Shaza Mohamed Elreweny, Master, 01090700297, Dr_shaza_elreweny@yahoo.com
About this study
Official title: Evaluation of Neutrophil/Lymphocyte Ratio, Platelet /Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia
Evaluation of neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP as markers of severity of Pre-eclampsia
- Conditions
- Pre-Eclampsia
- Being tested
- Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP
- Medical subject headings
- Pre-Eclampsia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRPDiagnostic test
Lab
| Study group | Role | What they receive |
|---|---|---|
| Neutrophil/lymphocyte ratio | Other | Not described Receives: Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP |
| Platelet/lymphocyte ratio | Other | Not described Receives: Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP |
| CRP | Other | Not described Receives: Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP |
What is being measured
The primary outcome is the main question the study is designed to answer.
PREECLAMPSIA
Measured: 6months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Aug 2018
- Study start1 Aug 2018
- Primary completion10 Aug 2018
- Study completion10 Aug 2018 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pre-EclampsiaStudies of the same condition, open and under way.
- More trials run by Ain Shams UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind
- Who is masked
- Care provider
- Enrolment
- 111 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Ain Shams University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Shaza Mohamed Elreweny, Ain Shams University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT03630276
- Sponsor's protocol ID
- Shaza Elreweny
- Status last verified
- Aug 2018
- First submitted
- 10 Aug 2018
- Last updated
- 14 Aug 2018
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 14 Aug 2018. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of Neutrophil/Lymphocyte Ratio, Platelet /Lymphocyte Ratio and CRP as Markers of Severity of Pre-eclampsia
- ClinicalTrials.gov ID
- NCT03630276
- Acronym / sponsor ID
- Shaza Elreweny
- Conditions
- Pre-Eclampsia
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 111 participants (estimated)
- Lead sponsor
- Ain Shams UniversityUniversity, hospital or other
- Study start
- 1 Aug 2018 (actual)
- Primary completion
- 10 Aug 2018 (actual)
- Study completion
- 10 Aug 2018 (estimated)
- First posted
- 14 Aug 2018 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Evaluation of neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP as markers of severity of Pre-eclampsia
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Single group
- Masking
- Single blind (care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Neutrophil/lymphocyte ratio | Other | Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP |
| Platelet/lymphocyte ratio | Other | Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP |
| CRP | Other | Diagnostic Test: Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP |
Who may qualify
- Ages
- 25 to 45 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (1 listed)
- PREECLAMPSIA from 25_45years
Key exclusion criteria (1 listed)
- chronic diseases Primary hypertension
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRPLab | Diagnostic test | CRP, Neutrophil/lymphocyte ratio, Platelet/lymphocyte ratio |
Primary outcome
PREECLAMPSIA
Time frame: 6months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Aug 2018.
Related trials for Pre-Eclampsia
Recruiting
Exercise to Improve Heart and Metabolic Health After Childbirth in Women at High Risk for Preeclampsia
Postpartum Exercise, Cardiometabolic Health
RecruitingObservational study
Molecular Study of the Maternal-fetal Interface in Preeclampsia.
Preeclampsia
Active, not recruitingObservational study
The CoPenHagen PREeClampsia and cardIOvascUlar diSease Study
Pre-Eclampsia, Atherosclerosis
RecruitingObservational study
Estimated Risk of Preeclampsia in the First Trimester and Its Association With Subclinical Atherosclerosis and Cardiovascular Risk in Women With Type 1 Diabetes
Type 1 Diabetes, Preeclampsia
Not yet recruitingPhase 2
Furosemide vs Placebo in Severe Preeclampsia Postpartum
Severe Preeclampsia
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Neutrophil/lymphocyte ratio, Platelet /lymphocyte ratio and CRP in people with Pre-Eclampsia, run by Ain Shams University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Aug 2018. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
PREECLAMPSIA (time frame: 6months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Aug 2018.